Related content

ERβ overexpression results in endocrine therapy resistance and poor prognosis in postmenopausal ERα-positive breast cancer patients

By          

Oncology Letters, Vol. 11, Iss. 2, 2016-01 ,pp. : 1531-1536

Spandidos Publications

Access to resources Recommend Favorite

HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer

By Lipton Allan   Goodman Laurie   Leitzel Kim   Cook Jennifer   Sperinde Jeff   Haddad Mojgan   Köstler Wolfgang   Huang Weidong   Weidler Jodi   Ali Suhail   Newton Alicia   Fuchs Eva-Marie   Paquet Agnes   Singer Christian   Horvat Reinhard   Jin Xueguang   Banerjee Joyee   Mukherjee Ali   Tan Yuping   Shi Yining   Chenna Ahmed   Larson Jeff   Lie Yolanda   Sherwood Thomas   Petropoulos Christos   Williams Stephen   Winslow John   Parry Gordon   Bates Michael  

Breast Cancer Research and Treatment, Vol. 141, Iss. 1, 2013-08 ,pp. : 43-53

Springer Publishing Company

Access to resources Recommend Favorite

Influence of Neoadjuvant Therapy with Epirubicin and Docetaxel on the Expression of HER2/ neu in Patients with Breast Cancer

By Taucher Susanne  

Breast Cancer Research and Treatment, Vol. 82, Iss. 3, 2003-01 ,pp. : 207-213

Springer Publishing Company

Access to resources Recommend Favorite

Akt expression and compartmentalization in prediction of clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab

By                  

International Journal of Oncology, Vol. 41, Iss. 4, 2012-01 ,pp. : 1204-1212

Spandidos Publications

Access to resources Recommend Favorite

Promoter methylation status of the FHIT gene and Fhit expression: Association with HER2/neu status in breast cancer patients

By            

Oncology Reports, Vol. 30, Iss. 5, 2013-01 ,pp. : 2270-2278

Spandidos Publications

Access to resources Recommend Favorite